Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures
- 1 October 1990
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 20 (10) , 2293-2299
- https://doi.org/10.1002/eji.1830201019
Abstract
Epstein‐Barr virus (EBV)‐negative Burkitt lymphoma (BL) lines are poor stimulators in allogeneic mixed lymphocyte cultures compared to EBV‐transformed lymphoblastoid cell lines derived from the same individuals. We have previously shown that the stimulatory capacity of the tumor cells is increased after EBV conversion (Avila‐Carino et al., Int. J. Cancer 1987. 40: 691). As a first step towards the identification of the viral gene product responsible for this change we have studied the influence of the EBV latent membrane protein (LMP) on the stimulatory capacity of the EBV‐negative BL lines BL41 and DG75 and the B lymphoma line BJAB. Four LMP‐transfected sublines of BL41, four DG75 LMP transfectants and one LMP‐transfected subline of BJAB showed a significantly stronger stimulatory capacity than the original line. The effect was directly proportional to the amount of LMP detected in each transfectant but was not due to reactivation of LMP‐specific memory cells since lymphocytes from EBV‐seropositive and ‐seronegative individuals responded equally. In order to define the relation between LMP expression and induction of stimulatory capacity, DG75 was transfected with constructs containing the LMP gene under the control of an heat‐shock promoter. The peak of LMP expression in heat shock‐treated cells preceded the appearance of stimulatory capacity by 6–12 h suggesting that critical amounts of the protein may be required to induce the phenotypic change recognized by the T cells. LMP influenced in a dose‐dependent manner the expression of the adhesion molecules LFA‐1, LFA‐3 and ICAM‐1 and B cell activation markers CD23 and CD39 in transfected sublines of BL41, but did not affect the expression of these markers in the DG75 and BJAB cell line. All LMP‐expressing transfectants showed an increased capacity to form conjugates with unprimed allogeneic lymphocytes.This publication has 52 references indexed in Scilit:
- The Epstein-Barr Virus ProteinsPublished by Elsevier ,1988
- Identification of a cell‐surface glycoprotein mediating cell adhesion in EBV‐immortalized normal B cellsInternational Journal of Cancer, 1986
- Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.Proceedings of the National Academy of Sciences, 1986
- Epstein–Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillanceNature, 1985
- Secretion of γ‐Interferon at the Cellular LevelScandinavian Journal of Immunology, 1984
- Monoclonal antibodies to epstein‐barr virus‐induced, transformation‐associated cell surface antigens: Binding patterns and effect upon virus‐specific t‐cell cytotoxicityInternational Journal of Cancer, 1982
- Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein–Barr virusNature, 1981
- Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitroNature, 1977
- X-LINKED RECESSIVE PROGRESSIVE COMBINED VARIABLE IMMUNODEFICIENCY (DUNCAN'S DISEASE)The Lancet, 1975
- Classification and biological nature of established human hematopoietic cell linesInternational Journal of Cancer, 1975